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A B S T R A C T
Intratympanic glucocorticoid therapy aims to reduce the side effects associated with systemic long-
time therapy of inner ear diseases or traumata after cochlear implantation. For that purpose,
thermoreversible hydrogels being ﬂuid at room temperature but solid at body temperature are known
to be appropriate drug delivery systems. In this work, the two key parameters sol–gel transition time
and temperature of Poloxamer 407 (POX 407) based hydrogels containing oto-compatible micronized
triamcinolone acetonide (TAAc) were evaluated by rheological experiments varying the concen-
trations of the different compounds. A 20% POX 407 hydrogel in PBS containing 30% TAAc emerged as
the most appropriate formulation. Oscillation–rotation–oscillation studies at two temperature levels
were found to be an useful in-vitro test system for the hydrogel which revealed sufﬁcient storage
stability at 4 C, injectability of the sol, solidiﬁcation within 20 s at body temperature and persistent
stiffness indicating prolonged adhesion at the round window membrane. According to the in-vitro
release studies using the TranswellTM system, absorption of the poor water soluble TAAc is partly due
to the low amount of dissolved drug but predominantly due to micellar transport resulting in a
cumulative release of 262.6  13.4 mg TAAc within one week followed by a sustained release of
193.1 8.3 mg TAAc within the next three weeks. Thus, the formation of POX 407 micelles is the basis
not only for gel formation but also absorptivity of TAAc. All in all, ﬁne tuned rheological experiments
and absorption studies emerged as useful tools for preclinical evaluation of intratympanally
administered hydrogels.
ã 2014 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
1. Introduction
As opposed to conventional systemic therapy, which suffers
from pronounced side effects in case of long-term treatment, local
glucocorticoid therapy of inner ear diseases or traumata after
cochlear implantation is a new and patient-friendly approach (Bird
et al., 2007). Unfortunately, unfavorable physiological conditions
such as low blood ﬂow in the cochlea as well as the blood–
perilymph barrier limit therapeutic efﬁcacy of drugs in cochlear
ﬂuids. In an effort to reach therapeutically relevant drug levels in
the inner ear aqueous solutions of dexamethasone or
betamethasone were administered intratympanally. These for-
mulations, however, suffered from rapid drainage through the
Eustachian tube and thus low drug levels in the inner ear due to
short contact time with the round window membrane (Bird et al.,
2007, 2011; Ye et al., 2007). To counteract the latter, semi-solid
formulations were administered directly on the round window
membrane and led to improved drug delivery into the inner ear
due to prolonged contact with the membrane (Wang et al., 2011).
According to Plontke et al. (2002), the amount of drug permeating
into the cochlea depends mainly on the residence time of the drug
on the round window membrane.
Out of these reasons, the thermoreversible characteristics of the
oto-compatible (Piu et al., 2010; Wang et al., 2009), FDA-approved
and autoclavable Poloxamer 407 (POX 407) (Dumortier et al., 2006;
Guzman et al., 2006), being ﬂuid at room temperature and semi-
solid at 37 C, seems to be most convenient for intratympanic
administration. POX 407 is a triblock copolymer consisting of two
hydrophilic polyethylene glycol end chains and a hydrophobic
Abbreviations: POX 407, Poloxamer 407; TAAc, Triamcinolone acetonide; DEX,
Dexamethasone; POX 188, Poloxamer 188; ORO-test, Oscillation–rotation–oscilla-
tion test.
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polypropylene glycol core block. Upon increasing the temperature,
POX 407 molecules arrange to form micelles which subsequently
aggregate to become a semi-solid hydrogel (Dumortier et al.,
2006).
In general, the anti-inﬂammatory and immunosuppressive
effects of glucocorticoids are best known, and they exert long-term
effects on the tissue reaction against foreign objects like cochlear
implants (Enticott et al., 2011). POX 407 gels containing
dexamethasone (DEX) have been successfully used in several
studies (Wang et al., 2011; Piu et al., 2010; Wang et al., 2009; Salt
et al., 2011), and proved oto-compatibility with preservation of
hearing thresholds. However, to the best of our knowledge there is
a lack of studies about POX 407 gels containing triamcinolone
acetonide (TAAc) for intratympanal administration although it
is well established in clinical use, considered safe and preserves
residual hearing together with a protective effect on hair cells
(Ye et al., 2007; Guzman et al., 2006). The concentrations of TAAc
applied in this study were related to the relative glucocorticoid
potential of DEX as well as the release of DEX in therapeutically
relevant levels as demonstrated by Piu et al. (2010) so that the
efﬁcacy of formulations containing 6% DEX and 30% TAAc might be
comparable.
The aim of this work was to develop and characterize POX 407
based hydrogels with emphasis on the sol–gel transition tempera-
ture and sol–gel transition time upon varying the POX 407- and the
TAAc-content. For that purpose, different rheological experiments
as well as an adopted release model were applied. Additionally, the
utility of additives such as POX 188, Miglyol, inorganic salts and
ions (Dumortier et al., 2006; Müller Goymann and Luisana, 2011)
to tune the sol–gel transition temperature is elucidated. All in all,
this in-vitro study should offer a deeper insight into the structural
characteristics as well as the release mechanisms of micelle-based
hydrogels.
2. Materials and methods
2.1. Materials
Micronized triamcinolone acetonide (TAAc) was purchased
from Fagron (Barsbüttel, Germany). Micronized dexamethasone
(DEX) was obtained from Gatt-Koller (Absam, Austria). Pluronic1
F-127 Prill (Poloxamer 407, POX 407) was bought from BASF
(Lampertheim, Germany). Pluronic1 F-68 (Poloxamer 188, POX
188) was acquired from Sigma–Aldrich (Vienna, Austria). 24-well-
plates and ﬁlter inserts (ThinCertTM - 24 Well, Pore ø 0.4 mm,
translucent, PET Membrane Ro Trac1) were from Greiner
(Kremsmünster, Austria). All other chemicals were purchased
from Sigma–Aldrich and were of analytical grade.
2.2. Methods
2.2.1. Hydrogel preparation
The hydrogel was manufactured according to Schmolka (1972)
by the “cold technique” using 10 mM phosphate buffered saline
(PBS) pH 7.4 instead of water, and the POX 407 solution has been
stored overnight at 4 C prior use. Drug-loaded gels were prepared
by homogeneously dispersing micronized particles of either TAAc
or DEX (180 or 20 mm) in the ﬂuid gel matrix by vortexing and
storing at 4 C overnight prior use.
2.2.2. Sol–gel transition time
Thermosensitivity of the POX 407 hydrogel was determined by
incubating 15–25% POX 407 solutions in PBS at 37 C. In brief,
100 ml POX 407 solution at 4 C was transferred into an Eppendorf
cup and subsequently incubated at 37 C. After 5, 10, and 20 min,
the Eppendorf cups were inverted and solidiﬁcation was assessed.
2.2.3. Rheological characterization
The reversibility of the sol–gel transition was investigated by
placing the cold formulation (4 C) into an Eppendorf cup,
incubating for 15 min at 37 C to become rigid, and then storing
the gel in a refrigerator to liquefy again. This procedure was
repeated 10 times. The state of aggregation was assessed after
inverting the cup.
The hydrogel's rheological characteristics were examined with
a Modular Compact Rheometer MCR 302 equipped with a cone/
plate system (CP50-1-SN27364; 50 mm/1 cone plate; Anton Paar,
Graz, Austria). All measurements were done in a Peltier controlled
hood, and the data were processed using the Rheoplus/32 V3.61
software. The storage modulus G0 and the loss modulus G00 were
calculated from the complex shear modulus G* as follows:
G0 ¼ GcosðdÞ (1)
G0 ¼ GsinðdÞ (2)
tanðdÞ ¼ G
00
G0
(3)
To deﬁne the linear viscoelastic region (LVR) shear strain
amplitude sweeps were carried out increasing the deformation
from 0.001 to 100% at an angular frequency of 3 rad s1 (Grüning
and Müller-Goymann, 2008).
Frequency sweep experiments were performed at a constant
deformation of 0.1% (20% POX 407; w/v) or 0.01% (20% POX 407
containing 30% TAAc; w/v) and decreasing the angular frequency
from 100 to 0.01 rad s1.
Temperature-dependent characteristics of the preparations
were elucidated in the range from 4 C up to 42 C at a heating
rate of 1 C min1 in the oscillatory mode setting the angular
frequency at 3 rad s1 and the deformation at 0.1% without and
0.01% with TAAc, respectively.
Additionally, an oscillation–rotation–oscillation (ORO) test was
accomplished at the same oscillation settings as above. In brief,
during the ﬁrst oscillatory mode the formulation was maintained
for 200 s at 4 C until the temperature increased up to 10 C within
30 s. Subsequently, the rotation mode was performed at 10 C for
30 s at the shear rate of 5000 s1, which simulates the injection
process (injection needles LUER G27: 0.4  42 mm) and was
calculated according to Eq. (4):
g ¼ 4  V
p  R3  t
(4)
where g is the calculated shear rate, V is the efﬂuent volume, R is
the radius, and t is the time.
Finally in the second oscillatory mode, the bottom plate was
warmed up to 37 C (0.2 C s1) within 135 s and maintained at 37 C
for 120 s, subsequently the temperature was increased up to 42 C.
All experiments, performed with a sample volume of 600 ml
and at a cone gap of 0.101 mm, were repeated at least 3 times.
2.2.4. Release studies
In a preliminary attempt to establish a release model without a
membrane barrier, 150 ml of a 20% POX 407 hydrogel colored by
addition of 0.005% aqueous Evans Blue were transferred into an
Eppendorf cup and incubated for 15 min at 37 C. The solidiﬁed gel
was overlain with 70 ml 1% aqueous 2-ethoxy-6,9-diaminoacridine
lactate solution of 37 C and further incubated at body temperature
for 24 h. The images were acquired at deﬁned times.
As a release model including a barrier, translucent ﬁlter inserts in
24-well plates were applied using artiﬁcial perilymph as an acceptor
medium. The aqueous artiﬁcial perilymph was composed of 137 mM
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2 and 1 mM NaHCO3, but
without 11 mM glucose to avoid bacterial contamination.
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After pre-soaking the polyethylene terephthalate membrane
(0.4 mm pore diameter) of the ﬁlter inserts in artiﬁcial perilymph
for 30 min at room temperature 100 ml cold, liquid gel were
applied on the ﬁlter, and the well-plate was incubated for 20 min at
37 C. After solidiﬁcation of the hydrogel, 300 ml artiﬁcial
perilymph were transferred to the acceptor chamber so that the
artiﬁcial perilymph was at the same level as the membrane of the
ﬁlter insert.
At predetermined time points 200 ml aliquots were withdrawn
from the acceptor compartment. Additionally, in an effort to collect
the entire permeated drug and to dissolve precipitated corticoid,
the ﬁlter insert was removed and the residual ﬂuid in the lower
chamber was mixed with 300 ml mobile phase. These two samples
were pooled to yield ﬁnally 600 ml sample per time point to be
assayed by HPLC. To continue the release study, the ﬁlter insert was
transferred to a new well, and 300 ml fresh artiﬁcial perilymph
were added.
The release studies were carried out at 37 C under low-germ
condition and repeated 3 times. Statistical analyses were carried
out by using ANOVA.
2.2.5. Quantitation of TAAc and DEX
The amount of released drug was determined by UV-detection
at 240 nm following HPLC using an Agilent 1100 System (Agilent
Technologies, Palo Alto, USA) equipped with a vacuum degasser, a
quaternary pump, an autosampler, a column compartment
thermostated at 25 C, a diode array detector and the Agilent
ChemStation software. 20 ml of the sample were separated in an
Acclaim1 120 C18 reversed-phase LC column (2.1 mm  150 mm,
3 mm; Thermo Fisher Scientiﬁc, Vienna, Austria) at a ﬂow rate of
0.5 ml min1 using a mobile phase of 60 parts acetonitrile and 40
parts 2 mM aqueous ammonium acetate, pH 3.2 adjusted with
formic acid (TAAc) or 40 parts bidistilled water (DEX), respectively
(César et al., 2011). The retention time was 1.75 and 1.37 min for
TAAc and DEX, respectively. The overall runtime was 5 min.
Calibration graphs using mobile phase containing 50%
artiﬁcial perilymph with or without 1% human serum albumin
(HSA) (Swan et al., 2009) as a diluent were prepared in the range
of 1–100 mg ml1 TAAc. The quality control samples were made in
the same way with deﬁned amounts of drug in the range of the
calibration graph.
3. Results
3.1. Sol–gel transition of the POX 407 formulation
In general, the solidiﬁcation time at 37 C decreased with
increasing POX 407 content, but at the same time the viscosity of
the solutions at 4 C increased making pipetting of the required
small volume of 50 ml difﬁcult (Fig. 1). Within the range of 15–25%
solutions, 20% POX 407/PBS formulations possessed an optimal
solidiﬁcation time of about 10 min.
3.2. Amplitude sweep experiments
The LVR of the 20% POX 407 preparations with or without TAAc
was determined by measuring the storage modulus (G0) and the
loss modulus (G00) as a function of a shear strain amplitude sweep
at 37 C. According to Mezger (2011), the viscoelastic state is the
region where G0 exceeds G00 and the LVR is characterized by a
plateau and parallel behavior of G0 and G00 (Fig. 2). The end of the
LVR, the so-called yield point, is the point where G0 decreases
indicating the beginning of alteration of the internal structure of
the hydrogel. In case of 20% POX 407-hydrogels/PBS containing 30%
TAAc, the LVR ends at 0.16% deformation whereas without the drug,
the yield point was at 0.39%. Consequently, to retain the internal
structure during the measurements, in all further experiments the
deformation was set at 0.01% for hydrogels containing TAAc and at
0.1% for hydrogels without the drug, respectively.
3.3. Frequency sweep experiments
To simulate stability of the hydrogel after intratympanic
administration frequency sweep experiments of 20% POX 407/
PBS preparations without and with 30% TAAc were performed at
37 C. As required for hydrogels, the storage modulus exceeded the
loss modulus by about 74,400 Pa, and the course of the curve was
nearly parallel to the x-axis at low frequency ranges from
0.01 rad s1 up to 20 rad s1 (Fig. 3). As a rule of thumb, storage
moduli >10 Pa at 0.01 rad s1 indicate stability of dispersions. Thus,
Fig. 1. Sol–gel transition of the thermoreversible hydrogel assessed by the tube
inversion method.
Fig. 2. Amplitude sweep of 20% POX 407/PBS containing 30% TAAc at 37 C showing
the LVR characterized by the plateau and parallel behavior of G0 and G00 .
Fig. 3. Frequency sweep of 20% POX 407/PBS containing 30% TAAc at 37 C.
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the storage moduli of the hydrogel with and without TAAc
amounting to 123,000 Pa and 4860 Pa additionally conﬁrm
preservation of the gel structure.
3.4. Temperature sweep experiments
The inﬂuence of sweeping the temperature on storage modulus
and loss modulus was investigated for various POX 407-based
hydrogels in order to determine the speciﬁc sol–gel transition
temperature (Tsol!Tgel). At 4 C all preparations were Newtonian
liquids as indicated by loss moduli exceeding the storage moduli.
Upon increasing the temperature, the Tsol!Tgel is reached where
the storage module is equal to the loss module and the ﬂuid is
converted into a plastic solid. Concurrently, the shear stress steeply
increases. Further rise of the temperature inverts the initial ratio
between loss and storage moduli to become ﬁnally independent
from temperature. According to Table 1, the presence of salts
decreases the Tsol!Tgel by 3.4 C, whereas the addition of 6–30%
steroid has no effect. In accordance with the literature (Dumortier
et al., 2006; Müller Goymann and Luisana, 2011), Miglyol as well as
POX 188 increase the Tsol!Tgel by 1.4 C and 5.4 C, respectively.
Although the Tsol!Tgel was not altered by the amount of steroid
added, the stiffness of the hydrogel as indicated by the complex
shear modulus is quite different as compared to the hydrogel
without TAAc; this parameter is nearly constant for 6% TAAc but
increases 2.3-fold in case of 30% steroid-content.
3.5. Oscillation–rotation–oscillation experiments
To estimate in-vitro the inﬂuence of high shear forces on the
thixotropic behavior during intratympanic injection ORO-
studies were performed (Fig. 4). Concurrently, the inﬂuence
of body temperature was assessed by adjusting the temperature
levels. During the ﬁrst oscillation mode within the LVR at 4 C
representing storage conditions, the preparations were ﬂuid as
indicated by 10-fold higher loss moduli as compared with the
storage moduli. The shear forces in the course of squeezing
the preparation through the injection needle were imitated by
the subsequent rotation mode at 10 C leading to a decrease in
viscosity. Finally, the situation at the round window membrane
is mimicked by the second oscillation mode at 37 C. Due to the
increased temperature, the preparations became semi-solid as
indicated by inversion of the ratio between loss modulus and
storage modulus in agreement with the results of the
temperature sweep studies. Finally, after reaching the Tsol!Tgel
transition, the preparations became solid within 20 s, and the
storage modulus exceeded the loss modulus about 10-fold. In
comparison with the temperature sweep experiments, the
Tsol!Tgel transition now shifted from 25.1 C to 28 C (20%
POX 407/PBS) or from 25 C to 28.9 C (20% POX 407/PBS with
30% TAAc) due to previous rotation. Prolonging the oscillation
and increasing the temperature up to 42 C did not alter the
storage, and the loss modulus so that a stable consistency at the
site of administration can be expected.
3.6. Release studies
As a prerequisite for release studies, the HPLC-method for
quantitation of the steroids was adapted and validated. The
calibration graphs revealed excellent linearity for TAAc in presence
and absence of human serum albumin (R2 = 0.9994 and R2 = 0.9998)
and DEX (R2 = 0.9997) in the concentration range of 1–100 mg ml1.
Table 1
Sol–gel transition temperatures of various POX 407 based hydrogels.
Gel type Addition of Sol–gel-transition temperature (C, mean  0.75) D C cf/20% POX 407/water Complex shear modulus at 37 C
20% POX 407/water 28.0 0.0 8820
20% POX 407/PBS 24.6 3.4 12,433
20% POX 407/PBS 30% TAAc 24.4 3.6 29,100
20% POX 407/PBS 6% TAAc 24.8 3.2 12,100
20% POX 407/PBS 6% DEX 24.5 3.5 10,400
20% POX 407/PBS 1% Miglyol 26.0 2.0 11,700
20% POX 407/PBS 0.5 POX 188 30.0 +2.0 9260
18% POX 407/PBS 27.4 0.6 6150
Fig. 4. ORO test of a 20% POX 407/PBS hydrogel containing 30% TAAc to simulate the intratympanal application. The ﬁrst oscillation mode (“O1”) indicates long-term stability
at 4 C, the rotation mode (“R”) exerts high shear forces occurring during injection at 10 C, and the second oscillation mode (“O2”) represents the gelation process upon
increasing the temperature and the stability of the hydrogel at the round window membrane.
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The addition of HSA had no signiﬁcant inﬂuence (p > 0.05) on the
TAAc quantiﬁcation. The lower limit of detection and the lower
limit of quantitation was 0.1 mg ml1 and 1 mg ml1 in case of TAAc,
0.05 mg ml1 and 0.1 mg ml1 in case of DEX. The inter-day
precision for 15 days and the intra-day precision was 2.1% or
0.9% in case of TAAc and 1.9% or 1.8% in case of DEX.
In a preliminary assay, the applicability of the release model
without barrier was assessed roughly by covering the blue dyed
hydrogel with yellow release medium. Within 24 h, a green
supernatant was observed indicating dissolution of the hydrogel.
Consequently, a barrier representing the round window mem-
brane is necessary to approach in-vivo conditions.
Using a membrane with 0.4 mm pore diameter and 30 mm
thickness as a barrier, the cumulative release of TAAc from the
individual POX 407 hydrogels after 30 days was in the range from
1.0% to 1.6% (Fig. 5). In detail, however, the total amount of drug
released from 30% TAAc hydrogels was quite different: lowest
release with no signiﬁcant difference (p > 0.05) was observed in
case of 18% POX 407/PBS and 20% POX 407/water amounting to
311.3  4.9 mg TAAc and 305.3  8.9 mg TAAc, respectively. Incor-
poration of 0.5% POX 188 in 20% POX 407/PBS hydrogels increased
the cumulative release to 355.0  18.7 mg TAAc. Among all the
formulations investigated, 20% POX 407/PBS hydrogels exhibited
highest cumulative release of 455.7  16.2 mg TAAc.
For comparison, the release proﬁles of 20% POX 407/PBS
hydrogels loaded with either 6% TAAc or DEX were examined
(Fig. 6). Applying the same conditions as above, the cumulative
release of TAAc was 1.6  0.1% corresponding to 98.0  5.3 mg after
30 days as opposed to 5.9  0.2% corresponding to 356.6  9.4 mg
drug in case of DEX. Besides, the saturation concentration of TAAc
in AP at 37 C is 12.1 0.3 mg ml1 or 139.89  1.66 mg ml1 in AP
containing 5% POX 407. All release proﬁles follow the kinetic model
of Higuchi (Higuchi, 1961) with a coefﬁcient of determination
>0.943 or >0.897 for the hydrogel containing 6% TAAc.
4. Discussion
The closely interacting key-parameters for applicability of in-
situ forming thermoreversible drug delivery systems in the inner
ear are the time and the temperature required for sol–gel
transition. On the one hand, the time frame should be long
enough to allow save intratympanic administration of the
preparation, on the other hand duration of surgery should be as
short as possible to reduce the length of anesthesia during cochlear
implantation. The solidiﬁcation time has to be ﬁne tuned with the
sol–gel transition temperature (Tsol!Tgel), as the solution should
become semi-solid at body temperature as soon as possible to
avoid loss by Eustachian drainage.
A simple tube inversion test as well as rheology revealed that a
20% POX 407/PBS solution gels within 10 min at 37 C. As elucidated
by temperature sweep experiments, the Tsol!Tgel increased with
decreasing POX 407 content,because gelationis promoted byhigher
availability of POX 407 micelles (Dumortier et al., 2006; Ricci et al.,
2002). The addition of even high amounts of steroid did not alter the
Tsol!Tgel, but provoked a tenfold lower deformation of the hydrogel.
This increase in stiffness due to presence of drug microparticles
(30% TAAc) in between the micelles is also displayed by a complex
shear modulus exceeding that of the plain hydrogel 1.3 fold. In spite
of the high solid content, the stability of the hydrogels was not
adversely affected since the course of the storage moduli was still
parallel to the x-axis at low frequencies.
Moreover, the presence of ions and inorganic salts being
components of PBS decreased the Tsol!Tgel by 3.4 C in comparison
to ion-free formulations. According to Ricci et al. (2002), the
afﬁnity of water to ions is higher than that to POX 407 so that the
lack of water molecules in between the micelles facilitates gelation
resulting in lower Tsol!Tgel. Concurrently, the complex shear
modulus increased by a third, which points to increased stiffness as
well as bioadhesiveness according to the literature (Dumortier
et al., 2006; Ricci et al., 2002; Choi et al., 1999). Especially the latter
effect is supposed to be beneﬁcial since a long contact time at the
round window membrane is desired.
A quite opposite effect on Tsol!Tgel was observed upon addition
of POX 188 or Miglyol. These substances increase the gelation
temperature and have been reported to disturb the micellization
process (Dumortier et al., 2006; Choi et al., 1999). In general,
frequency sweep experiments conﬁrmed long-term stability of all
tested hydrogels. Altogether, the 20% POX 407/PBS hydrogel
containing 30% TAAc emerged to be the most appropriate
formulation.
The oscillation–rotation–oscillation experiments at tempera-
ture levels chosen according to the expected environment in the
middle ear proved to be most useful for prediction of the practical
applicability of the hydrogels. The rheological parameters during
the ﬁrst oscillation mode at 4 C conﬁrmed storage stability of the
solutions, the rotation mode at 10 C mimicking high shear forces
proved injectability of the formulation, and ﬁnally the second
oscillation mode at 37 C simulated the situation at the round
window membrane. Upon contact with the absorption barrier, the
formulation undergoes gelation after a short delay of 19.5 s, and the
inner structure of the gel is maintained as tan d remains constant
indicating long-term stiffness of the hydrogel and thus prolonged
residence at the membrane.
The subsequent absorption of TAAc at the round window
membrane was simulated applying a membrane model with a pore
diameter smaller than that of the drug microparticles. Considering
that the ﬂow of the perilymph is about 2–4 nl min1, and the
Fig. 5. In-vitro release proﬁles of different POX 407 hydrogels containing 30% TAAc
using the trans-well system with a polyethylene terephthalate membrane over a
period of 30 days (mean  SD < 10.9).
Fig. 6. In-vitro release proﬁle of 20% POX 407/PBS containing 6% DEX or 6% TAAc
over a period of 30 days. (mean  SD  4.40).
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estimated volume is 12–16 ml (Schaaf, 2012; Salt et al., 2006), 300 ml
artiﬁcialperilymphwere usedasanacceptormedium.Thisvolumeis
a compromise between assay practicability and physiology. Never-
theless, non-sink conditions prevail in-vitro and in-vivo as the
saturation concentrationwas determined to be about 10 mg TAAc/ml
artiﬁcial perilymph at 37 C.
The release mechanism is supposed to be guided by the spatial
distribution of TAAc in the gel matrix: (i) the dissolved proportion of
TAAc accumulates inthe hydrophobic core of the micelles. Incase of a
20% POX 407/PBS hydrogel, up to 6% TAAc might be incorporated into
micelles as the stiffness of the hydrogel as represented by the
complex shear modulus was comparable to that without drug. (ii)
The insoluble, micronized proportion of the steroid is distributed in
between the POX 407 micelles. Consequently, the absorption of TAAc
might be mainly due to micellar transport. This assumption is
underlined by the fact that the cumulative release of TAAc from 20%
POX 407/PBS hydrogels exceeds that from 18% hydrogels by 68% due
to higher availability of POX 407 micelles. Additionally, after micellar
transport across the membrane, the TAAc precipitated in the
acceptor compartment, because the POX 407 concentration deceeds
the critical micelle concentration, and the TAAc exceeds its
saturation solubility. Moreover, the insoluble drug contributes to
increased stiffness of the hydrogel as indicated by a 2.3-fold higher
complex shear modulus of the 30% TAAc hydrogel.
At similar POX 407 concentrations, the cumulative release from
a 6% and a 30% TAAc hydrogel was only slightly different
amounting to 1.6  0.1% and 1.5  0.1%. However, the cumulative
amount of permeated drug from 30% TAAc hydrogels was 4.6-fold
higher. The presence of POX 188 reduced the cumulative release by
about a ﬁfth due to disturbance of micellization as already
observed during rheological examinations.
Interestingly, at 6% drug loading, the cumulative release of DEX
was 3.6-fold higher than that of TAAc. Thus, solubility is another
parameter inﬂuencing release from Poloxamer hydrogels, as the
aqueous solubility of DEX is reported to be 10–1000 times higher
than that of TAAc (Block and Patel, 1973; Behl et al., 1976).
In general, the in-vitro release proﬁles indicate an initial burst
within the ﬁrst week releasing up to 262.6  13.4 mg TAAc followed
by a sustained release of 193.1 8.3 mg TAAc within the next three
weeks, which might also be beneﬁcial for in-vivo administration.
5. Conclusion
All in all, oscillation–rotation–oscillation experiments to
simulate storage stability, injection as well as solidiﬁcation of
the formulation at the site of administration combined with
release studies using the TranswellTM system to mimic the in-vivo
drug transport were found to be most useful tools to establish and
optimize TAAc-loaded thermoreversible hydrogels for intratym-
panal administration.
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